In January 2020, Janssen began working with industry partners, governments and health authorities to develop a vaccine candidate to help treat COVID-19. In March 2021, the European Commission granted a conditional marketing authorisation for our first single-dose COVID-19 vaccine.
Janssen’s single-dose COVID-19 vaccine, also known as JNJ-78436735 or Ad26.COV2.S, is an inactivated adenovirus vector (like the common cold virus) containing the DNA that codes for the coronavirus ‘spike’ protein. When a person receives the Janssen COVID-19 vaccine, their cells are used to make the ‘spike’ protein, which is then recognised by the immune system as foreign.This causes an immune response which leads to antibodies (proteins that help kill off bacteria and viruses) being created. Should a vaccinated person then get infected with SARS-CoV-2, the antibodies previously generated will be able to fight it off.
Our COVID-19 vaccine programme leverages Janssen’s AdVac® technology. To learn more about this technology click here.
EMEA. EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU. Available from: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-jansse.... Last accessed: July 2021.
CDC. Understanding Viral Vector COVID-19 Vaccines. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/vi.... Last accessed: July 2021.
CDC. Symptoms. Available from: https://www.cdc.gov/adenovirus/about/symptoms.html. Last accessed: July 2021.